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Abstract
Introduction: Despite minimal evidence, public concerns that the human papillomavirus (HPV) 
vaccine can cause autoimmune diseases (AD) persist. We evaluated whether HPV vaccine is 
associated with a long-term increased risk of diabetes mellitus type 1 (DM1).
Methods: This was a retrospective cohort study in which we identified all potential DM1 cases 
from Kaiser Permanente Northern California (KPNC) members who were between 11 and 26 
years old any time after June 2006 through December 2015. We chart reviewed a random sample 
of 100 DM1 cases to confirm diagnosis and to develop a computer algorithm that reliably 
determined symptom onset date. Our DM1 Analysis Population comprised all individuals who met 
membership criteria and who were age and sex eligible to have received HPV vaccine. We 
adjusted for age, sex, race, Medicaid, and years of prior KPNC membership by stratification using 
a Cox multiplicative hazards model with a calendar timeline.
Results: Our DM1 analysis included 911,648 individuals. Of 2613 DM1 cases identified, 338 
remained in the analysis after applying our algorithm, HPV vaccine eligibility and membership 
criteria. Over the 10 years of the study period, comparing vaccinated with unvaccinated persons, 
we did not find an increased risk of DM1 associated with HPV vaccine receipt (hazard ratio 1.21, 
95% Confidence Interval0.94, 1.57).
Conclusions: We found no increased risk for development of DM1 following HPV vaccination. 
Our study provides reassurance that during the 10-year time period after HPV vaccine was 
introduced, there was no substantial increased risk for DM1 following HPV vaccination.
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1. Introduction
The U.S. Food and Drug Administration approved the quadrivalent HPV vaccine (4vHPV) 
for females between the ages of 9 and 26 years for prevention of HPV-related cancers and 
warts in June 2006 [1]. The vaccine was approved for use in males in 2009. A nine-valent 
HPV vaccine (9vHPV) was approved for use in males and females in 2014 and for an 
expanded age range in males 19–26 years in 2015 [2,3]. Clinical trials and post-licensure 
studies have shown the 4vHPV vaccine to be safe and well-tolerated [4–6]. Routine 
vaccination with HPV vaccine at age 11 or 12 years has been recommended by the Advisory 
Committee on Immunization Practices (ACIP) since 2006 for females and since 2011 for 
males [7,8].
Routine use of HPV vaccine among girls and boys in early adolescence combined with 
heightened parental worries regarding adverse events has led to persistent public concerns 
that this vaccine can cause autoimmune diseases (AD). Multiple studies have evaluated 
several AD and to date there is minimal evidence to suggest an association between HPV 
vaccine and any AD [9–15]. These studies have provided reassurance, although data with 
long-term follow-up after vaccination have been limited.
In response to lingering public concerns and to provide longer term data, we conducted a 
single site study within the Vaccine Safety Datalink (VSD) to assess potential long-term 
associations between HPV vaccine and multiple AD. The objective of this current study, 
conducted as part of this larger AD investigation, was to evaluate whether receipt of HPV 
vaccine is associated with a subsequent increased risk of diabetes mellitus type 1 (DM1).
2. Methods
2.1. Study setting
We conducted this study in Kaiser Permanente Northern California (KPNC), an integrated 
healthcare delivery system, which has more than 4 million members and an annual birth 
cohort of approximately 40,000. KPNC owns all their hospitals and clinics, and their 
electronic medical record captures all outpatient, emergency department, and inpatient visits, 
as well as all immunizations, laboratory, pharmacy, radiology and demographic data. All 
vaccines, including HPV, are provided at no additional cost and members and providers are 
electronically prompted for appropriate immunizations. Because the study period included 
use of both the 4vHPV and the 9vHPV (KPNC did not use the 2 valent HPV vaccine), the 
term “HPV vaccine” refers to both 4vHPV and 9vHPV vaccines throughout.
2.2. Autoimmune disease (AD) study population
The larger retrospective AD cohort study evaluated for longterm risk of 18 AD following 
HPV vaccination (manuscript in preparation). In brief, this AD study population included all 
members of KPNC who were age-eligible to receive HPV vaccine beginning either July 
2006 for females (when it first became available at KPNC for females) or October 2011 for 
males (when it was first recommended for males) through December 31, 2015. Since KPNC 
routinely targets HPV immunization at 11 years of age (in line with ACIP 
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recommendations), we identified all HPV vaccines administered to individuals after their 
10th birthday and searched for potential AD first diagnosed after their 11th birthday. The 
AD study population served as the underlying population for the 18 AD analyses, applying 
criteria specific for each AD. The AD study population was comprised of 1,580,797 
individuals who contributed follow-up time during the study period for all 18 AD, including 
for the DM1 analyses described below.
2.3. Diabetes mellitus type 1 (DM1) case identification and chart review sample
We identified potential DM1 cases using internal diagnostic codes specific for DM1, and 
included the terms DM1, type 1 diabetes mellitus, “with” any other insulin dependent 
condition and excluded the terms DM2, type 2, non-insulin, and any “history of”. We 
verified completeness by cross-checking the mapping to ICD 9 diagnostic codes 250.XX. 
Irrespective of HPV exposure status, we selected the first lifetime diagnosis to ensure that it 
was an incident case of DM1.
2.3.1. Chart review—We chart reviewed a sample of cases to assess whether a 
subsequent analysis using all electronically identified DM1 cases without chart review 
would be feasible based on the following: (1) a sufficiently high chart confirmation rate of 
electronically identified cases; (2) the ability to determine an onset date of DM1 symptoms; 
and (3) the ability to estimate symptom onset date with acceptable accuracy based on the 
specificity and consistency with which symptom onset timing was described in the chart 
(e.g., “3–4 weeks ago” vs “1–2 years ago”).
To assure that all ages and both genders were represented in the chart review (i.e., we 
included older male adolescents), we identified all DM1 cases from members who were 
between 11 and 26 years old at any time after June 2006, regardless of eligibility to have 
received HPV vaccine. We then selected a random sample for chart review.
Considering these criteria together allowed us to assess whether we could define a time 
period between symptom onset and diagnosis (“lag period”) which could be applied to all 
cases in the analysis prior to the diagnosis date, regardless of chart review status. We 
carefully defined a lag period as described in the results below to ensure that we did not 
misclassify HPV vaccine status at the time of DM1 symptom onset.
2.3.2. KPNC membership criteria—We also assessed the length of KPNC 
membership prior to DM1 diagnosis that would be required to assure that cases were 
incident.
Taking into account the feasibility assessment results and KPNC membership requirements, 
as described in the results, we determined that an analysis using electronically identified 
DM1 cases without chart review would be feasible and reliable.
2.4. DM1 analysis population
All individuals in the cohort who were age and sex eligible to have received HPV vaccine, 
and who met the KPNC membership criterion described in the results below comprised the 
DM1 analysis population.
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2.5. Statistical analysis
This was a cohort analysis that included all individuals in the DM1 analysis population. 
Both incidence of DM1 and HPV vaccination rate varied by age, sex and other factors 
during the study time period (Tables 1, 2 and Supplemental Figure). We adjusted for these 
and other factors by stratification using a Cox multiplicative hazards model with a calendar 
timeline. We stratified by age in 6-month categories, sex, race, Medicaid status, and years of 
prior KPNC membership; the calendar timeline provided stratification by calendar day.
We did not include the “lag period” prior to the DM1 diagnosis in the analyses and excluded 
DM1 cases who were vaccinated during the “lag period”. Thus, all analyses compared the 
risk of DM1 in people who were beyond the lag period after their 1st HPV vaccine with 
people who were as yet unvaccinated.
We performed sensitivity analyses to evaluate the possible impact of discrete classification 
of risk factors, sparse data, and outliers. We performed separate analyses in males and 
females and in age groups where vaccine delivery patterns differed over time. We assessed 
sparse data by performing stratified exact analysis. We assessed level of classification for 
age by performing a multiplicative hazards model with an age timeline (restricted to 
comparing people who were born within 14 days of each other). We assessed influence of 
outliers by performing analyses with and without the most extreme risk sets (those with 
extremely low or high proportions of vaccinated individuals, where a single DM1 case could 
potentially cause a large change in our effect estimates). Each of these sensitivity analyses 
reduced various potential biases, but at the expense of reduced precision and power. We 
conducted all analyses using SAS version 9.3 (SAS Institute, Inc., Cary, NC).
3. Results
3.1. Feasibility assessment of an analysis using non-chart reviewed DM1 cases
We identified 2613 potential DM1 cases from the larger chart review population, and 
randomly selected 100 for review. Chart review confirmed that 98 (98%) were true cases of 
DM1, with the remaining 2% being diabetes mellitus Type 2. For the 98 confirmed cases, 
everyone had a symptom onset date documented, and the onset date of symptoms could be 
reliably estimated in most cases. In this sample, the symptom onset date was within 6 
months prior to 1st DM1 diagnosis for everyone who had at least 1 year of membership. 
Based on clinical judgment and chart review findings, we therefore considered that a lag 
period of 180 days between symptom onset and diagnosis could reliably and consistently be 
applied to all DM1 cases who have had at least one year of prior KPNC membership.
3.2. DM1 cases for analysis
Of the 2613 identified DM1 cases, 1140 (43.6%) occurred in those who were eligible to 
receive HPV vaccine (Fig. 1). Of these 1140 cases, 445 (39.0%) had at least 1 year of KPNC 
membership before diagnosis and no disenrollment of 6 months or longer since becoming 
eligible for HPV vaccine. Of these 445 DM1 cases, 388 (87.2%) were diagnosed at least 6 
months after becoming eligible to receive HPV vaccine (i.e., after the lag period) and were 
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therefore included in the analysis. Of these, 123 (31.7%) had received an HPV vaccine and 
265 (68.3%) were unvaccinated at time of symptom onset.
3.3. DM1 analysis
The 1.58 million individuals in the AD study population decreased to 911,648 after we 
applied all DM1 analysis population criteria. Of the 911,648 in the DM1 analysis 
population, 330,200 (36.2%) received ≥1 dose of HPV vaccine by the end of their follow up 
and 581,448 (63.8%) did not (Table 1). The proportion of all follow-up time that was after 
vaccination was 0.31 (Table 2). As expected, more females than males received 1 dose of 
HPV vaccine (62.9% vs 37.1%, Table 1) and females also had a larger proportion of post-
vaccination follow-up time (0.37 vs 0.19; Table 2). Regardless of vaccination status, overall 
DM1 incidence in the analysis population was 1.2 per 10,000 person-years and generally 
decreased with increasing age (Fig. 2). DM1 incidence trended higher among males in our 
study population, although it was not statistically significantly different (hazard ratio [HR] 
1.24, 95% confidence interval [CI] 0.92, 1.65. P = 0.154 and Supplemental Figure).
Multiplicative hazards analysis anchored on calendar date and stratified on age, membership, 
race, Medicaid status and controlling for sex comparing vaccinated with unvaccinated did 
not demonstrate an increased risk of DM1 associated with HPV vaccine (HR 1.21, 95% CI 
0.94, 1.57; Table 3).
Sensitivity analyses stratified by sex and exact analyses were similar, as were analyses based 
on an age timeline, those limited to those less than 26 years of age, and analyses leaving out 
the most unbalanced risk sets. All sensitivity analyses produced relative risk estimates near 
1, but with wider confidence intervals, as would be expected (Table 3). In addition, analyses 
which included a utilization measure the year before HPV eligibility did not change the 
results (HR 1.21, 95% CI 0.93, 1.57, P = 0.15).
4. Discussion
In this study, we evaluated risk of new onset DM1 following HPV vaccination during the 
first 10 years of routine use of HPV vaccine and found no evidence of an association 
between HPV vaccine receipt and development of DM1. Despite DM1 occurring more 
commonly among males in our study population, a previously observed phenomenon, our 
analysis limited to males did not detect an increased risk for DM1 after HPV vaccination 
[16,17]. Our study provides several important advantages over prior studies. First, we 
confirmed via chart review sample that nearly all identified DM1 cases were true cases. We 
applied a 6-month period prior to DM1 diagnosis to account for the timing of symptom 
onset and the lag time to diagnosis to ensure that we correctly assigned vaccination status at 
the time DM1 symptoms would have begun. Finally, and importantly, our study assessed for 
new onset DM1 over a decade of real-world use of the HPV vaccine. Using these rigorous 
analytic criteria, this study found no association between HPV vaccination and long-term 
development of DM1.
In general, our findings are consistent with prior studies. We previously conducted an 
observational study assessing the general safety of 4vHPV in more than 180,000 vaccinees 
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from both Northern and Southern California Kaiser Permanente and did not note any 
association between DM1 and receipt of 4vHPV [10]. Autoimmune-specific safety analyses 
performed separately as part of this larger 4vHPV safety study noted a decreased association 
between 4vHPV and new onset DM1 (incidence rate ratio 0.57, 95% CI 0.47, 0.73). This 
finding was based on small numbers of cases in which the timing of disease onset had no 
clear relationship with vaccination [9]. A French case-control study similarly found no 
association between DM1 and 4vHPV vaccine receipt (odds ratio 1.2, 95% CI 0.4, 3.6), nor 
did another French cohort study (HR 1.07, 95% CI 0.87, 1.31), while a recent Danish study 
among males did not identify an association between HPV vaccination and DM1 (rate ratio 
0.80, 95% CI 0.40, 1.6) [13,15,18].
A large study in Denmark and Sweden evaluating AD among females during the 180 days 
following HPV vaccination found a statistically significant association with DM1 (rate ratio 
[RR]1.29, 95% CI 1.03, 1.62), as well as with Behcet’s disease (RR 3.37, 95% CI 1.05, 
10.80) and Raynaud’s disease (RR 1.67, 95% CI 1.14,2.44) [12]. However, after the authors 
applied three predefined criteria (“reliability of analysis”, “strength of association” and 
“consistency”), none met all three (DM1 only met the “reliability” criteria), and they 
concluded that there was no consistent evidence for a causal association. Our study differs 
from this study in several important ways. Our population included males and was racially 
and ethnically diverse. We also had a longer exposure period and looked for DM1 any time 
after vaccination within the study period. In addition, we excluded the 6-month time-period 
prior to diagnosis because during that time period, it would be unclear if the onset of disease 
came before or after the vaccine. We conducted medical record review to confirm cases and 
onset date, thus we had high confidence that our vaccinated cases had symptom onset after 
vaccination. Finally, background incidence of diabetes varies by age, for which we 
controlled very finely.
In our study of DM1 we were able to address a number of challenges inherent in studying 
AD. First, we found that specific, welldefined initial symptoms of DM1 were nearly always 
documented in our medical records. From our sample chart review, we found that we could 
consistently determine when symptoms began with a reasonable degree of accuracy. The 
initial presentation of DM1 in adolescents is typically acute and can be severe, thus patients 
usually seek care soon after onset of symptoms [19,20]. We were therefore able to reliably 
estimate a lag time between symptom onset and DM1 diagnosis which we could confidently 
apply to all cases, regardless of chart review. These methods of DM1 case detection should 
be useful in future studies. Finally, because these specific factors meant that we could 
conduct a credible analysis using nonchart reviewed cases, we were able to analyze a larger 
number of cases.
However, this study faced unusual and specific challenges related both to the changing 
recommendations for adolescent HPV vaccine use and changes to KPNC family 
memberships during the study period. In our study population, the likelihood of having 
received HPV vaccine varied dramatically depending on calendar year, age, and sex. Studies 
of AD following adolescent vaccination must consider that during the late teen years, many 
adolescents leave their parent’s health plan to go to school and work and these individuals 
could no longer be included in the study population. For this reason, we lost a large fraction 
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of our potential follow up time after HPV vaccination. Since females began receiving HPV 5 
years earlier than males, many of them had 5 more years during which they could have a gap 
in membership and be excluded from the study population. Consequently, since 2011, there 
were many more males in the older teenage groups than there were females of similar age. 
Together, these factors created a dynamic variation in the age-sex composition of our study 
population over time, and it was critical that we correctly adjusted for age and sex in our 
analyses so that we did not produce spurious results.
4.1. Limitations
We acknowledge that our study had limitations. Many males could not be included in the 
analysis because HPV was only recommended for males starting late in 2011. It is also 
possible that people who received HPV vaccine as a catch-up (i.e., at ages older than the 
recommended 11 or 12 years) may have been different in unmeasured ways than people who 
received HPV vaccine as part of routine scheduled well care. Similarly, our comparison 
group of people who never received HPV vaccine may have also differed in unmeasured 
ways from vaccinated people. Finally, our study population suffered from informative 
censoring (i.e., receipt of HPV vaccine was correlated with continued membership, dropout 
rates differed for vaccinated and unvaccinated persons). We attempted to mitigate this by 
close matching on years of prior membership, but this does not fully eliminate the problem. 
Finally, the results of all the sensitivity analyses suggest that there was residual confounding 
that we were unable to address.
5. Conclusions
Our large retrospective cohort study found no increased longterm risk for development of 
DM1 following HPV vaccination during the 10-year study period. Based on our DM1 case 
ascertainment in this study, it is feasible to monitor the safety of HPV vaccine with regard to 
DM1 using automated data. While safety assessments of HPV vaccine, as for all vaccines, 
are ongoing, our study provides reassurance that there is no substantial increased risk for 
DM1 after HPV vaccination.
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Fig. 1. 
Flow chart of DM1 case disposition, Kaiser Permanente Northern California (KPNC) 2006–
2015.
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Fig. 2. 
Diabetes mellitus type I incidence by age and HPV vaccination status after applying lag 
period and membership criteria, Kaiser Permanente Northern California 2006–2015.
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Table 1
Vaccination status and sex for diabetes mellitus type 1 analysis population, 2006–2015.
Sex Ever HPV vaccinated during study period
N = 330,200
No record of HPV vaccination during study period
N = 581,448
Total*
N = 911,648
Female 207,561 (62.9%) 292,145 (50.2%) 499,706
Male 122,639 (37.1%) 289,303 (49.8%) 411,942
*
Included all individuals who met membership criteria and who were age and sex eligible to have received HPV vaccine during the study period.
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